Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Herantis Pharma plc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Herantis Pharma plc. - Product Pipeline Review - 2014', provides an overview of the Herantis Pharma plc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Herantis Pharma plc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Herantis Pharma plc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Herantis Pharma plc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Herantis Pharma plc.'s pipeline products Reasons to buy - Evaluate Herantis Pharma plc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Herantis Pharma plc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Herantis Pharma plc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Herantis Pharma plc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Herantis Pharma plc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Herantis Pharma plc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Herantis Pharma plc. Snapshot 4 Herantis Pharma plc. Overview 4 Key Information 4 Key Facts 4 Herantis Pharma plc. - Research and Development Overview 5 Key Therapeutic Areas 5 Herantis Pharma plc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Herantis Pharma plc. - Pipeline Products Glance 9 Herantis Pharma plc. - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Herantis Pharma plc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Herantis Pharma plc. - Drug Profiles 12 Small Molecule for Immunology, Ophthalmology, Oncology and Dermatology 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 HER-902 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 LX-1101 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Recombinant Protein for Amyotrophic Lateral Sclerosis 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Herantis Pharma plc. - Pipeline Analysis 18 Herantis Pharma plc. - Pipeline Products by Target 18 Herantis Pharma plc. - Pipeline Products by Route of Administration 19 Herantis Pharma plc. - Pipeline Products by Molecule Type 20 Herantis Pharma plc. - Pipeline Products by Mechanism of Action 21 Herantis Pharma plc. - Recent Pipeline Updates 22 Herantis Pharma plc. - Dormant Projects 23 Herantis Pharma plc. - Locations And Subsidiaries 24 Head Office 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables Herantis Pharma plc., Key Information 4 Herantis Pharma plc., Key Facts 4 Herantis Pharma plc. - Pipeline by Indication, 2014 6 Herantis Pharma plc. - Pipeline by Stage of Development, 2014 7 Herantis Pharma plc. - Monotherapy Products in Pipeline, 2014 8 Herantis Pharma plc. - Phase II, 2014 9 Herantis Pharma plc. - Phase I, 2014 10 Herantis Pharma plc. - Preclinical, 2014 11 Herantis Pharma plc. - Pipeline by Target, 2014 18 Herantis Pharma plc. - Pipeline by Route of Administration, 2014 19 Herantis Pharma plc. - Pipeline by Molecule Type, 2014 20 Herantis Pharma plc. - Pipeline Products by Mechanism of Action, 2014 21 Herantis Pharma plc. - Recent Pipeline Updates, 2014 22 Herantis Pharma plc. - Dormant Developmental Projects,2014 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.